- Home
- VNDA vs CMPX Comparison
VNDA vs CMPX Comparison
Compare VNDA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- CMPX
- Stock Information
- Founded
- VNDA 2002
- CMPX 2014
- Country
- VNDA United States
- CMPX United States
- Employees
- VNDA N/A
- CMPX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- CMPX Health Care
- Exchange
- VNDA Nasdaq
- CMPX Nasdaq
- Market Cap
- VNDA 270.2M
- CMPX 236.7M
- IPO Year
- VNDA 2006
- CMPX N/A
- Fundamental
- Price
- VNDA $4.94
- CMPX $1.38
- Analyst Decision
- VNDA Strong Buy
- CMPX Strong Buy
- Analyst Count
- VNDA 2
- CMPX 3
- Target Price
- VNDA $15.50
- CMPX $7.67
- AVG Volume (30 Days)
- VNDA 643.5K
- CMPX 503.1K
- Earning Date
- VNDA 11-06-2024
- CMPX 11-12-2024
- Dividend Yield
- VNDA N/A
- CMPX N/A
- EPS Growth
- VNDA N/A
- CMPX N/A
- EPS
- VNDA N/A
- CMPX N/A
- Revenue
- VNDA $190,858,000.00
- CMPX $850,000.00
- Revenue This Year
- VNDA $5.13
- CMPX N/A
- Revenue Next Year
- VNDA $42.65
- CMPX $747.71
- P/E Ratio
- VNDA N/A
- CMPX N/A
- Revenue Growth
- VNDA N/A
- CMPX N/A
- 52 Week Low
- VNDA $3.46
- CMPX $0.77
- 52 Week High
- VNDA $6.75
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- VNDA 50.36
- CMPX 34.67
- Support Level
- VNDA $4.82
- CMPX $1.27
- Resistance Level
- VNDA $5.55
- CMPX $1.46
- Average True Range (ATR)
- VNDA 0.22
- CMPX 0.14
- MACD
- VNDA -0.02
- CMPX -0.05
- Stochastic Oscillator
- VNDA 32.22
- CMPX 15.07
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.